Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05892744 · ClinicalTrials.gov registry record · Phase 4
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
A Phase 4 study of Major Depressive Disorder and Chronic Major Depression, Recurrent, sponsored by University of Texas at Austin.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05892744: Recruiting Phase 4 study of Major Depressive Disorder and Chronic Major Depression, Recurrent, sponsored by University of Texas at Austin.
NCT05892744 is a Phase 4 study of Major Depressive Disorder and Chronic Major Depression, Recurrent that is actively recruiting participants, run by University of Texas at Austin. The registered enrollment target is 50 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05892744, a Phase 4 study of Major Depressive Disorder and Chronic Major Depression, Recurrent, is actively recruiting participants, sponsored by University of Texas at Austin.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.
Primary Outcome
Standardized clinician-administered measure of depression symptom severity. Scores range from 0-52. Lower scores indicate less depressive symptomatology, and so are the more desirable.
Conditions Studied
Interventions
- DRUG Sertraline
Study Locations (1)
Texas
- Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-09-30 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 4 |
What NCT05892744 shows while recruiting
NCT05892744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Sertraline is the first listed.
NCT05892744 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05892744 about?
NCT05892744 is a clinical study titled "Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression". The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is...
What is the current status of trial NCT05892744?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2023-09-30. Estimated completion is 2027-07-15.
What conditions does trial NCT05892744 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Chronic Major Depression, Recurrent.
What interventions are being tested in trial NCT05892744?
The interventions under investigation include: Sertraline (DRUG).
Who is sponsoring clinical trial NCT05892744?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05892744 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05892744's enrollment target sits among peer trials
50 183rd of 282 higher than 97 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
-
Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI